JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Omeros Corp

Închisă

SectorSănătate

7.65 -0.78

Rezumat

Modificarea prețului

24h

Curent

Minim

7.59

Maxim

7.91

Indicatori cheie

By Trading Economics

Venit

8M

-25M

Marjă de profit

-8,121.359

Angajați

202

EBITDA

9.3M

-26M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+71.63% upside

Dividende

By Dow Jones

Următoarele câștiguri

12 nov. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

284M

561M

Deschiderea anterioară

8.43

Închiderea anterioară

7.65

Sentimentul știrilor

By Acuity

18%

82%

29 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

Omeros Corp Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

15 oct. 2025, 15:36 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion -- Update

15 oct. 2025, 13:27 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk to Pay Omeros Up to $2.1 Billion for Blood Disease Drug

15 oct. 2025, 12:33 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk: Omeros Could Recieve Up to Total of $2.1B Including Potential Milestones, Tiered Royalties

15 oct. 2025, 12:32 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk: Omeros Eligible to Receive $340M in Upfront and Near-Term Milestone Payments

15 oct. 2025, 12:32 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk Will Be Granted Exclusive Global Rights to Develop, Commercialise Zaltenibart in All Indications

15 oct. 2025, 12:32 UTC

Achiziții, Fuziuni, Preluări

Novo Nordisk, Omeros in Asset Purchase and License Pact for Omeros' Rare Blood and Kidney Disorder Drug

Comparație

Modificare preț

Omeros Corp Așteptări

Obiectiv de preț

By TipRanks

71.63% sus

Prognoză pe 12 luni

Medie 13.13 USD  71.63%

Maxim 20 USD

Minim 6.269 USD

În baza a 3 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruOmeros Corp - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

3 ratings

2

Cumpărare

1

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

6.265 / 7.49Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Weak Bullish Evidence

Sentiment

By Acuity

29 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
help-icon Live chat